FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					- 0.		,,,,	(11) 01 1110	investi	incine c	Joinparty Act	01 10-10								
1. Name and Address of Reporting Person* <u>Campbell Bradley L</u>						2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [FOLD] 5. Relationship of Reporting Person(s) to (Check all applicable)										on(s) to Iss	uer			
						11111000 11111111111111111111111111111								X Direct		or		10% Ov	/ner	
(Last) (First) (Middle)					3. 1	Date of Earliest Transaction (Month/Day/Year)								X	Officer below)			Other (s below)	pecify	
C/O AMICUS THERAPEUTICS, INC.					05	05/01/2023								President & CEO						
3675 MA	ARKET STI	REET																		
					- 4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street)														Line)						
PHILAD	ELPHIA P	A	19104											X Form filed by One Reporting Person Form filed by More than One Reporting						
-					-										Persor		e urari	One Repor	ung	
(City)	(S	tate)	(Zip)																	
		Tab	le I - N	lon-Deri	ivativ	e Sec	curit	ties A	cquire	ed, D	isposed o	f, or B	enefic	ally	Owned					
1. Title of S	Security (Inst	r. 3)		2. Transac	tion	2A. Deemed Execution Date,			3. 4. Securities Acquired (A) or Transaction Disposed Of (D) (Instr. 3, 4 a									7. Nature of Indirect		
			(Month/Da	ıy/Year)			Code (Instr.		Disposed Of (D) (Instr. 3, 4 an			3)	Benefici	Beneficially		Indirect	Beneficial Ownership			
							iilii/Day/Tear)				(A) or			Reported Transaction(s)		(I) (Instr. 4)		(Instr. 4)		
								Code	V	Amount	(A) (I) (D)	Price		(Instr. 3						
Common Stock 05/01/202					2023	M 11,700 A \$2.45 835,154		5,154		D										
Common Stock 05/01/202					2023				S		11,700	D	\$11.80	028 ⁽¹⁾ 823,454		3,454	154 D			
		7	Гable I	I - Deriv	ative	Secu	ıritie	es Acc	uired	l, Dis	posed of,	or Be	neficia	lly O	wned	<u> </u>				
				(e.g.,	puts,	calls	s, Wa	arrant	s, opt	ions	, convertil	ble sec	urities	s)						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,			ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		ty D Si (li	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					0.4						Expiration		Amou or							
								l	Date				Numb of	.						
					Code	٧	(A)	(D)	Exerc	isable	Date	Title	Share	s		<u> </u>	_			
Stock Options (right to buy)	\$2.45	05/01/2023			M			11,700	(2	2)	01/03/2024	Common Stock	n 11,70	00	\$0	7,125		D		

Explanation of Responses:

- 1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$11.56 to \$11.89 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- $2. \ All \ of the options were fully vested and exercisable as of the transaction date.$

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2022.

/s/ Ellen S. Rosenberg, Attorney-in-Fact

05/03/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.